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The genetics of Alzheimer’s disease; putting flesh on the bones
For two decades the search for genes involved in Alzhei-
mer’s disease brought little reward; it was not until the
advent of genome-wide association studies (GWAS) that
genetic associations started to be revealed. Since 2009
increasingly large GWAS have revealed 20 loci, which in
itself is a substantial increase in our understanding, but
perhaps the more important feature is that these studies
have highlighted novel pathways that are potentially
involved in the disease process. This commentary assem-
bles our latest knowledge while acknowledging that the
casual functional variants, and undoubtedly, other genes
are still yet to be discovered. This is the challenge that
remains and the promise of next-generation sequencing is
anticipated as there are a number of large initiatives
which themselves should start to yield information before
long.
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Fifteen years separated the discovery of APOE, the first
genetic risk factor for sporadic, late-onset Alzheimer’s
disease (LOAD, also referred to as sporadic Alzheimer’s
disease – sAD), and the first replicable genome-wide asso-
ciations in 2009. However with patience comes reward; a
recent meta-analysis by the International Genomics of
Alzheimer’s Project (IGAP) reported 11 new Alzheimer’s
susceptibility loci (CASS4, CELF1, FERMT2, HLA-DRB5/
HLA-DRB1, INPP5D, MEF2C, NME8, PTK2B, SLC24A4/
RIN3, SORL1 and ZCWPW1), and confirmed eight
(CR1, BIN1, CD2AP, EPHA1, CLU, MS4A6A, PICALM and
ABCA7) of the nine previously reported genome-wide
associations in addition to APOE [1]; the exception being
CD33 which failed to replicate. Consequently genetic dis-
coveries within the last 5 years account for ∼47% of the
population attributable risk (PAR) of LOAD. This rises to
∼61% with the established APOE haplotype (Table 1).
However there is still a substantial component of ‘missing
heritability’ waiting to be detected, which may be
accounted for by multiple variants imparting modest effect
(polygenic model) and/or fewer rare mutations of larger
effect [4].
Unlike the rarer, early onset familial form of Alzhei-
mer’s disease (fAD), the result of deterministic mutations
in one of three amyloid processing genes (APP, PSEN1 or
PSEN2), the aetiology of LOAD remains unknown. Con-
sidering LOAD shares clinical and neuropathological fea-
tures with the familial disease, it is attractive to speculate
that abnormalities within the amyloid pathway are simi-
larly culpable. However, despite years of research, there is
no concrete evidence that the ‘amyloid cascade’ is causally
linked to late-onset disease, or to ratify its therapeutic
potential.
The era of the genome-wide association study (GWAS)
heralded the arrival of new LOAD alleles, each common
(minor allele frequency, MAF > 5%) and conveying
modest genetic effects [3,5–8]. Enrichment of the first
eight genome-wide associated genes within three path-
ways (cholesterol metabolism, immune system function
and synaptic vesicle recycling/endocytosis) [9,10] nomi-
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nated novel pathways for therapeutic intervention. While
these pathways may modify amyloid aggregation and/or
clearance, to what extent these they are implicated in
amyloid homeostasis remains to be determined [11,12]. A
summary of how these new genes link to pathways likely
to be involved in sAD is presented (see Figure 1).
New sAD genes, new pathways?
The IGAP consortium recently reported 11 new genes for
sAD (Table 1b) [1]. IGAP drew on a combined resource of
74 046 samples, the largest GWAS meta-analysis of LOAD
to date. The ensuing power boost elevated new risk alleles
previously masked due to low frequency, weak genetic
effects or incomplete tagging of the causal mutation. This
may explain why SORL1, which had long been suspected
of harbouring genuine disease alleles using candidate
gene approaches [13], attained genome-wide significance
in this series but not earlier GWAS. The encoded sortilin-
related receptor is a neuronal APOE receptor and is under-
stood to direct APP trafficking to amyloidogenic endocytic
pathways [14].
Similarly, immune system function is represented in
new candidate genes. Most notable are the association
signals within the HLA region (which encompasses a
number of candidate genes, the strongest associations are
found at DRB1 and DRB5). These genes have been previ-
ously associated with Parkinson’s disease [15] and multi-
ple sclerosis [16]. INPP5D encodes a member of the
inositol polyphosphate-5-phosphatase family of enzymes
involved in second messenger signalling in myeloid cells.
INPP5D affects pathways associated with cell proliferation
and the regulation of inflammatory responses [17].
The remaining genes (PTK2B, MEFC2, CASS4,
FERMT2, CELF1, ZCWPW1, SLC24A4, NME8) cannot be
readily attributed to pathways which are biologically rel-
evant to LOAD. Among them are cell adhesion molecules
and kinases which signal in pathways attributed to
Table 1. Population attributable fraction (PAF) calculations for alleles associated with Alzheimer’s disease
SNP Gene MAF Location Major/minor alleles OR PAF
(a)
rs4147929 ABCA7 0.16 Intronic G/A 1.15 (1.11–1.19) 2.8
rs6733839 BIN1 0.37 Intergenic C/T 1.22 (1.18–1.25) 8.1
rs10948363 CD2AP 0.26 Intronic A/G 1.10 (1.07–1.13) 2.3
rs9331896 CLU 0.40 Intronic T/C 0.86 (0.84–0.89) 5.3
rs6656401 CR1 0.19 Intronic G/A 1.18 (1.14–1.22) 3.7
rs11771145 EPHA1 0.35 Intergenic G/A 0.90 (0.88–0.93) 3.1
rs983392 MS4A6A 0.41 Intergenic A/G 0.90 (0.87–0.92) 4.2
rs10792832 PICALM 0.37 Intergenic G/A 0.87 (0.85–0.89) 5.3
rs429358 APOE4 0.12 Nonsynonymous T/C 4.89 (4.45–5.39) 27.3
rs75932628 TREM2 0.002 Nonsynonymous C/T 4.5 (1.7–11.9) 0.8
(b)
rs7274581 CASS4 0.08 Intronic T/C 0.88 (0.84–0.92) 1.1
rs10838725 CELF1 0.31 Intronic T/C 1.08 (1.05–1.11) 2.4
rs17125944 FERMT2 0.08 Intronic T/C 1.14 (1.09–1.19) 1.5
rs9271192 HLA 0.28 Intergenic A/C 1.11 (1.08–1.15) 3.2
rs35349669 INPP5D 0.46 Intronic C/T 1.08 (1.05–1.11) 4.6
rs190982 MEF2C 0.39 Intergenic A/G 0.93 (0.90–0.95) 2.7
rs2718058 NME8 0.37 Intergenic A/G 0.93 (0.90–0.95) 2.9
rs28834970 PTK2B 0.36 Intronic T/C 1.10 (1.08–1.13) 3.1
rs10498633 SLC24A4 0.21 Intronic G/T 0.91 (0.88–0.94) 1.5
rs11218343 SORL1 0.04 Intronic T/C 0.77 (0.72–0.82) 1.1
rs1476679 ZCWPW1 0.29 Intronic T/C 0.91 (0.89–0.94) 3.2
Total PAF 61.8
The top table (a) documents established alleles whereas the bottom table (b) is for the newly identified genes. For each gene the documented SNP
is the one achieving the greatest association in the IGAP publication [1]. The exception is TREM2 which is the first rare variant to be identified
from next-generation sequencing efforts (SNP details taken from Guerreiro et al. [2]), and APOE where the odds ratio (OR) is calculated from
in-house data sets (C. Medway and K. Morgan, unpublished). Combined PAF calculated according to equation reported by Naj et al. [3].
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neuronal function. PTK2B is a cytoplasmic protein
tyrosine kinase expressed in brain, where it is understood
to regulate neuronal activity via the MAP-kinase signal-
ling pathway. Specific functions in long-term potentiation
(LTP) and memory have been proposed [18]. MEF2C is
also expressed in the cortex and is involved in the MAP
kinase signalling pathway, responding to calcium influx to
activate survival genes [19]. MEF2C encodes a transcrip-
tion factor of the MEF2 family, which has a widely
reported role in muscle (cardiac and skeletal) and vascular
development [20]. Like PTK2B, MEFC2 has been impli-
cated in hippocampal synaptic plasticity and LTP [21].
Haploinsufficiency of MEF2C manifests mental retarda-
tion and epilepsy [22].
PTK2B is a focal adhesion kinase (FAK2), which is
known to interact with the CASS4 (also genetically impli-
cated in the IGAP series) homologue NEDD9 and integrin
to regulate apoptosis and cell adhesion [23]. While CASS4
encodes a poorly characterized scaffold protein, variants
in other members of the CAS gene family (NEDD9)
have been associated with dementia and Alzheimer’s
disease [24,25]. Fermitin family member 2 [FERMT2 or
kindling-2 (KIND2)] is a neuronally expressed adhesion
molecule implicated in actin cytoskeleton organization
[26]. FERMT2 also plays a role in signalling via integrin
activation and the Wnt signalling pathway [27]. Abnor-
mal Wnt signalling has previously attracted attention as a
candidate pathway in Alzheimer’s disease and other
dementing syndromes [28].
CELF1, ZCWPW1, SLC24A4 and NME8 are particu-
larly poorly characterized. CELF1 (CUGBP1 – CUG triplet
repeat-binding protein 1) encodes an RNA-binding
protein involved in alternative mRNA splicing, editing and
stability. A CUG triplet repeat expansion is responsible for
myotonic dystrophy type-1. Given the size of the associ-
ated locus in the IGAP publication, the causal gene may lie
further afield; a MAP-kinase activating death domain
130kb downstream has attracted attention although
RAPSN, a receptor-associated protein found at the
synapse, is also within this region. Similarly, the associa-
tion signal attributed to ZCWPW1 (rs1476679), encod-
ing an epigenetic regulatory protein [29], is part of a
larger LD block, encompassing many candidate genes.
SLC24A4 (NCKX4) is a sodium/potassium/calcium
exchanger expressed in human brain [30]. Variation in
SLC24A4 gene has been associated with hair, eye and skin
pigmentation [31]. More recently variation in SLC24A4
has been associated with lipid metabolism [32]. It is
important to note that the SLC24A4 association signal
(rs10498633) is towards the 3′-end of the gene, which
is neighboured by RIN3. RIN3 interacts with BIN1
(amphiphysin-2), and may be part of the endocytic
machinery [33]. Finally NME8, encoding a Thioredoxin
Domain-containing Protein, is associated with primary
ciliary dyskinesia-6 [34].
Towards identifying the causal alleles: why we
find genome-wide association signals
In each instance identification of the causal allele(s) will
be instrumental towards conclusively pinpointing the
affected gene, accurately attributing risk to each gene/loci,
and to fully appreciate the mechanism of pathogenesis.
However, given that the causal mutations underpinn-
ing earlier genome-wide associations remain largely
unknown this will be a considerable challenge. This
has led some to postulate that we need to dig deeper,
Figure 1. Pathways implicated in Alzheimer’s disease (AD).
Familial Alzheimer’s disease (FAD) is caused by one of three genes
(PSEN1, PSEN2 and APP) involved in the amyloid processing
pathway (‘the amyloid cascade’). There is no single pathway that
explains the more common nonfamilial, late-onset/sporadic
Alzheimer’s disease (LOAD/sAD). Candidate genes are enriched for
several pathways; Cholesterol Metabolism, Immune System and
Endocytosis. These pathways may be downstream dependent or
independent of amyloid processing.
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resequencing candidate loci to identify rare mutation(s)
explaining GWAS associations [35]. Coined ‘synthetic
associations’ [36], there is no evidence that any of the
common Alzheimer’s disease alleles discovered to date are
precipitated through correlation (linkage disequilibrium)
to rarer causal mutations. Furthermore, it would be
expected that GWAS ‘hits’ conforming to the synthetic
model will have allele frequencies skewed towards the
lower end of the allele spectrum, which is not the rule in
complex disorders [37]. The more common the associated
GWAS SNPs (single nucleotide polymorphisms), the larger
the effect (odds ratio) at the rare position(s) would have to
be to fully explain the signal – this makes it more likely that
they would have already been detected through family-
based linkage approaches [37]. IGAP reports three alleles
with frequencies below 10%. It will remain to be seen if, in
these instances, genome resequencing unearths rare
alleles evoking these signals as they represent the best
potential examples to date that are possibly compatible
with this concept.
Genome resequencing has already contributed to our
understanding of sAD genetics. Two independent groups
have reported rare coding variants within TREM2 (exon
2) conferring increased risk for LOAD [2,38]. TREM2
encodes a receptor expressed on myeloid cells, and is
understood to mediate anti-inflammatory responses.
Interestingly, this gene has been previously associated
with other dementing phenotypes; the rare recessive
Nasu-Hakola disease [39], early-onset dementia [40] and
frontotemporal-like dementia [41]. Although there is
evidence of allelic heterogeneity, with greater burden
in cases, carriers of one nonsynonymous change
(rs75932628, R47H) displayed effects sizes on par with
APOE ε4 allele carriers.
International Genomics of Alzheimer’s Project reports
a common variant (rs9381040), 3.4 kb downstream of
TREM2’s neighbour TREML2, which falls just short of
genome-wide significance. The fact that the alleles (R47H
and rs9381040) are in complete linkage disequilibrium
(D′ = 1) (there are no recombination hotspots segregating
these positions), coupled with the observation that the
TREM2 risk allele is in phase with the major allele at the
TREML2 SNP, is consistent with a synthetic model. This
would explain why the TREML2 minor allele reports a
protective effect while the TREM2 allele is associated with
risk. Interestingly, there is also prior linkage evidence of
the TREM2 locus in Alzheimer’s disease [42]. In order to
fully evaluate to what extent rare mutations in the TREM2
locus account for the TREML2 signal, a greater under-
standing of the allelic heterogeneity will have to be
sought. Interestingly this observation may represent the
interface, or juxta-positioning, of GWAS and NGS tech-
nologies. As GWAS are conducted with ever increasing
sample sizes they will undoubtedly start to uncover rarer
disease associated variants as exemplified by the IGAP
study. This bodes well for the concept that more in-depth
NGS will be able to contribute to some of the remaining
‘missing heritability’.
One recent observation that disease causing, coding
mutations for common disorders are relatively ‘young’ –
in fact occurred within the last 10 000 years [43]
adds impetus to the NGS drive. For a common variant
(MAF > 5%) to become fixed, and hence readily detectable
in a GWAS, the change needs to have occurred over
200 000 years ago. Previously we have been using
modern technologies to investigate ancient DNA changes;
we are on the verge of an era where we are now able to use
these approaches to look at ‘modern’ DNA changes, that
is, the contribution of rare variants with much lower
MAFs.
Putting flesh on the bones; osteoclasts,
microglia and Alzheimer’s disease
Defects in the TREM2-DAP12 signalling pathway in
osteoclasts and microglia, both of which are derived from
myeloid progenitor cells, may explain the duel bone and
brain manifestations in Nasu-Hakola disease. DAP12 and
TREM2 are both expressed in osteoclasts and microglia
(and dendritic cells and oligodendrocytes). Osteoclasts
oversee the demineralization, reabsorption and recycling
(via endocytosis) of bone; a similar recycling/removal
mechanism for microglia within the brain is plausible.
It is interesting to note that other LOAD candidate genes
have been implicated in osteoclast function downstream of
TREM2-DAP12 signalling. PTK2B (Pyk2) is one of the
kinases acting downstream of DAP12 [44]. INPP5D nega-
tively regulates osteoclast formation and function by
directly binding to DAP12 and preventing PI3K signalling
[45,46]. CASS4 family members (CASL and CASS1), a
downstream target of PTK2B, are required for bone
matrix remodelling [23] and expression is reduced in
TREM2 knockouts [40]. Siglecs (CD33-related family)
expressed in myeloid derived cells also signal via DAP12,
suggesting a common signalling pathway [47]. A
recent systems approach has championed microglia
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phagocytosis as a prominent functional group, where
DAP12 is a key regulator [48].
Consequently, there may be a mechanistic overlap
between TREM2/DAP12 and some of the GWAS derived
genes. The possibility of a shared mechanism between
the bone and neurological manifestations of Alzheimer’s
disease has been raised [49].
The future
The heritable component of sAD which remains elusive
may conform to a polygenic model (many more alleles of
weak genetic effects), and will require larger cohorts to
detect vanishingly smaller genetic effects. Polygenic risk
scoring in other complex diseases suggests this is indeed
the case [50]. Alternatively fewer, rarer variants confer-
ring larger genetic effects, like TREM2, may be responsible
[2]. While weak genetic effects (polygenic model) and rare
allele (rare variants model) are criticized for their individu-
ally small contributions to risk, the insight they offer into
disease biology is invaluable.
The time when GWAS and resequencing approaches
occupy their own niche is coming to an end; GWAS as a
tool to explore common variants (MAF > 5%) in suffi-
ciently large numbers to detect weak genetic effects
(OR > 1.3), and NGS as a tool to detect rare variants in
modest sample numbers due to cost implications. As
custom array technology begins to include rarer variants,
discovered through 1000 Genomes and/or other
resequencing initiatives, and whole-genome sequencing
becomes cost-effective these boundaries will blur. With
this will come a greater appreciation of how common and
rare alleles summate to influence a phenotype at any given
disease loci.
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